Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
Name:
Geographical Variation Leishma ...
Size:
178.3Kb
Format:
PDF
Description:
Main Article
Authors
Hailu, AsratMusa, Ahmed
Wasunna, Monique
Balasegaram, Manica
Yifru, Sisay
Mengistu, Getahun
Hurissa, Zewdu
Hailu, Workagegnehu
Weldegebreal, Teklu
Tesfaye, Samson
Makonnen, Eyasu
Khalil, Eltahir
Ahmed, Osama
Fadlalla, Ahmed
El-Hassan, Ahmed
Raheem, Muzamil
Mueller, Marius
Koummuki, Yousif
Rashid, Juma
Mbui, Jane
Mucee, Geoffrey
Njoroge, Simon
Manduku, Veronica
Musibi, Alice
Mutuma, Geoffrey
Kirui, Fredrick
Lodenyo, Hudson
Mutea, Dedan
Kirigi, George
Edwards, Tansy
Smith, Peter
Muthami, Lawrence
Royce, Catherine
Ellis, Sally
Alobo, Moses
Omollo, Raymond
Kesusu, Josephine
Owiti, Rhoda
Kinuthia, John
Affiliation
Addis Ababa University, Ethiopia; Institute of Endemic Diseases, University of Khartoum, Sudan; Centre for Clinical Research, Kenya Medical Research Institute, Kenya; Medecins Sans Frontieres, Amsterdam; Drugs for Neglected Diseases initiative (DNDi), Switzerland; Gondar University, Ethiopia; Arba Minch Hospital, Regional Health Bureau of SNNP state, Ethiopia; Faculty of Medicine, Gedaref University, Sudan; London School of Hygiene and Tropical Medicine, United KingdomIssue Date
2010-10-26Submitted date
2011-03-10
Metadata
Show full item recordJournal
PLoS Neglected Tropical DiseasesAbstract
Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is increasing. Improved treatment options are needed. Paromomycin was shown to be an efficacious first-line treatment with low toxicity in India.PubMed ID
21049059Type
ArticleLanguage
enISSN
1935-2735ae974a485f413a2113503eed53cd6c53
10.1371/journal.pntd.0000709
Scopus Count
Collections
Related articles
- Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
- Authors: Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M
- Issue date: 2012
- Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study.
- Authors: Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E
- Issue date: 2010 Oct 26
- Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
- Authors: Kimutai R, Musa AM, Njoroge S, Omollo R, Alves F, Hailu A, Khalil EA, Diro E, Soipei P, Musa B, Salman K, Ritmeijer K, Chappuis F, Rashid J, Mohammed R, Jameneh A, Makonnen E, Olobo J, Okello L, Sagaki P, Strub N, Ellis S, Alvar J, Balasegaram M, Alirol E, Wasunna M
- Issue date: 2017 Mar
- Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
- Authors: Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, Alnour M, Shah S, Chappuis F, van Griensven J, Zachariah R
- Issue date: 2015 Dec
- Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
- Authors: Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B
- Issue date: 2017 May